NCT01560585

Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.

Detailed description

Retinoids have some relevant characteristics that could be considered useful in treating AlZheimer's disease. These include anti-inflammatory properties, possible anti-amyloid formation proeprties and inhibition of cell cycle properties

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	Isotretinoin	Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks

Timeline

• Start date: 2012-04-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2012-03-22
• Last updated: 2022-06-15
• Results posted: 2022-06-15

Locations

1 site across 1 country: United States